This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida.
Background: A survey was carried out to investigate the relative importance of an...
Background: ALKS 3831, under development for the treatment of schizophrenia, is composed of olanzapine and samidorphan. In a prior study, samidorphan mitigated olanzapine-associated weigh...
Background: Combination olanzapine and samidorphan (OLZ/SAM) is in development for treatment of schizophrenia and bipolar I disorder and is intended to provide the antipsychotic efficacy ...
Objectives: Olanzapine effectively treats schizophrenia and bipolar I disorder (BD-I); however, its use is hindered by significant weight gain. A combination of olanzapine and samidorphan...
Background: A combination of olanzapine and samidorphan (OLZ/SAM) is in development for schizophrenia to provide the efficacy of olanzapine while mitigating olanzapine-associated weight g...